Factors Associated With Fecal Microbiota Transplant Failure in the Treatment of Recurrent Clostridioides difficile Infection: A Single-Center Retrospective Study

被引:2
|
作者
Warraich, Fatima [1 ]
Sohail, Syed H. [1 ]
Knee, Alexander [2 ]
Smith, Jacob [3 ]
Schlecht, Hans [3 ]
Skiest, Daniel [3 ]
机构
[1] Univ Massachusetts, Internal Med, Chan Baystate Med Ctr, Springfield, MA 01199 USA
[2] Univ Massachusetts, Off Res Epidemiol Biostat Res Core, Chan Baystate Med Ctr, Springfield, MA USA
[3] Univ Massachusetts, Infect Dis, Dept Hematol Oncol, Chan Baystate Med Ctr, Springfield, MA USA
关键词
fmt failure; recurrent c diff; gut biome; fecal microbiota transplantation (fmt); clostridioides difficile infection; VANCOMYCIN;
D O I
10.7759/cureus.45118
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BackgroundClostridioides difficile infection (CDI) is a major cause of hospital-acquired diarrhea and is associated with substantial morbidity and mortality. Recurrences following treatment are common. Fecal microbiota transplantation (FMT) is a therapeutic intervention in which stool from a healthy donor is administered to a patient with recurrent CDI. Studies to date of predictors of FMT failure have primarily included inpatients. In this study, we aimed to describe FMT failure rates within one year of FMT and evaluate factors associated with FMT failure.MethodologyWe conducted an exploratory retrospective study of consecutive patients who underwent outpatient FMT at a single tertiary care center in Western Massachusetts from December 2014 through September 2018. We collected patient data including demographics, CDI-related factors, and FMT-related factors. FMT failure was defined as non-response or recurrence of diarrhea, associated with positive stool C. difficile toxin or polymerase chain reaction. Unadjusted relative risk (RR) and 95% confidence intervals for factors associated with FMT failure were estimated using log-binomial regression. ResultsA total of 92 patients were included with a mean age of 64 years. CDI severity was mild or moderate in 73% and severe or fulminant in 27%. The most common FMT indication was recurrent CDI in 76% of patients. FMT failure occurred in 25 of 92 (27%) patients, with half occurring within 11 days. Factors associated with FMT failure were active malignancy (RR = 2.56), prior hospitalizations (RR = 2.42), and receipt of non-CDI antibiotics within six months of FMT (RR = 2.80). We did not observe strong associations for risk of FMT failure with age >= 65, sex, use of proton pump inhibitors or H2 receptor agonists, history of colectomy, immunosuppression, history of malignancy, diabetes, appendectomy, CDI severity, or probiotic use.ConclusionsActive malignancy, prior CDI hospitalizations, and non-CDI antibiotics within six months before FMT were associated with FMT failure in the outpatient setting. Knowledge of the above factors may help inform shared decision-making with patients at risk for FMT failure.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Déjà Vu: Unanswered Questions About Fecal Microbiota Transplantation for Recurrent Clostridioides difficile Infection
    Poutanen, Susan M.
    Hota, Susy S.
    CLINICAL INFECTIOUS DISEASES, 2024,
  • [32] Fecal microbiota spores, live-brpk (VOWST™/VOS) for prevention of recurrent Clostridioides difficile infection
    Berry, Parul
    Khanna, Sahil
    FUTURE MICROBIOLOGY, 2024, 19 (18) : 1519 - 1528
  • [33] Epidemiology and Outcomes of Recurrent C Difficile Infection Among Hematopoietic Cell Transplant Recipients: A Single-center, Retrospective 10-year Study
    Sanchez, Eduardo
    Krantz, Elizabeth M.
    Escobar, Zahra Kassamali
    Tverdek, Frank
    Rosen, Emily A.
    Oshima, Masumi Ueda
    Carpenter, Paul A.
    Pergam, Steven A.
    Liu, Catherine
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (10):
  • [34] The Efficacy and Safety of Fecal Microbiota Transplant for Recurrent Clostridium difficile Infection: Current Understanding and Gap Analysis
    Wilcox, Mark H.
    McGovern, Barbara H.
    Hecht, Gail A.
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (05):
  • [35] Early treatment for Clostridioides difficile infection: retrospective cohort study
    Drozdinsky, Genady
    Vronsky, Daniella
    Atamna, Alaa
    Ben-Zvi, Haim
    Bishara, Jihad
    Eliakim-Raz, Noa
    INTERNAL AND EMERGENCY MEDICINE, 2025, 20 (01) : 189 - 195
  • [36] Treatment and Outcomes of Clostridioides difficile Infection in Switzerland: A Two-Center Retrospective Cohort Study
    Filippidis, Paraskevas
    Kampouri, Eleftheria
    Woelfle, Maximilian
    Badinski, Tina
    Croxatto, Antony
    Galperine, Tatiana
    Papadimitriou-Olivgeris, Matthaios
    Grandbastien, Bruno
    Achermann, Yvonne
    Guery, Benoit
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (13)
  • [37] Real-world Use of Bezlotoxumab and Fecal Microbiota Transplantation for the Treatment of Clostridioides difficile Infection
    de la Villa, Sofia
    Herrero, Sergio
    Munoz, Patricia
    Rodriguez, Carmen
    Valerio, Maricela
    Reigadas, Elena
    Alvarez-Uria, Ana
    Alcala, Luis
    Marin, Mercedes
    Olmedo, Maria
    Kestler, Martha
    Chamorro, Esther
    Bouza, Emilio
    OPEN FORUM INFECTIOUS DISEASES, 2023, 10 (02):
  • [38] Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection
    Hvas, Christian Lodberg
    Jorgensen, Simon Mark Dahl
    Jorgensen, Soren Peter
    Storgaard, Merete
    Lemming, Lars
    Hansen, Mette Mejlby
    Erikstrup, Christian
    Dahlerup, Jens Frederik
    GASTROENTEROLOGY, 2019, 156 (05) : 1324 - +
  • [39] Effectiveness of fecal microbiota transplant for the treatment of Clostridioides difficile diarrhea: a systematic review and meta-analysis
    Pomares Bascunana, R. A.
    Veses, V.
    Sheth, C. C.
    LETTERS IN APPLIED MICROBIOLOGY, 2021, 73 (02) : 149 - 158
  • [40] Healthcare burden of recurrent Clostridioides difficile infection in Japan: A retrospective database study
    Kunishima, Hiroyuki
    Ito, Kaoru
    Laurent, Thomas
    Abe, Machiko
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2018, 24 (11) : 892 - 901